These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

736 related articles for article (PubMed ID: 23301632)

  • 1. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.
    Papp KA; Griffiths CE; Gordon K; Lebwohl M; Szapary PO; Wasfi Y; Chan D; Hsu MC; Ho V; Ghislain PD; Strober B; Reich K; ; ;
    Br J Dermatol; 2013 Apr; 168(4):844-54. PubMed ID: 23301632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up.
    Reich K; Papp KA; Griffiths CE; Szapary PO; Yeilding N; Wasfi Y; Ott E; Hsu MC; Lebwohl M; Gordon KB;
    J Drugs Dermatol; 2012 Mar; 11(3):300-12. PubMed ID: 22395580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials.
    Lebwohl M; Leonardi C; Griffiths CE; Prinz JC; Szapary PO; Yeilding N; Guzzo C; Li S; Hsu MC; Strober B
    J Am Acad Dermatol; 2012 May; 66(5):731-41. PubMed ID: 21930328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials.
    Gordon KB; Papp KA; Langley RG; Ho V; Kimball AB; Guzzo C; Yeilding N; Szapary PO; Fakharzadeh S; Li S; Hsu MC; Reich K
    J Am Acad Dermatol; 2012 May; 66(5):742-51. PubMed ID: 21978572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.
    Kimball AB; Gordon KB; Fakharzadeh S; Yeilding N; Szapary PO; Schenkel B; Guzzo C; Li S; Papp KA
    Br J Dermatol; 2012 Apr; 166(4):861-72. PubMed ID: 22356258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study.
    Kimball AB; Papp KA; Wasfi Y; Chan D; Bissonnette R; Sofen H; Yeilding N; Li S; Szapary P; Gordon KB;
    J Eur Acad Dermatol Venereol; 2013 Dec; 27(12):1535-45. PubMed ID: 23279003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies.
    Reich K; Langley RG; Lebwohl M; Szapary P; Guzzo C; Yeilding N; Li S; Hsu MC; Griffiths CE
    Br J Dermatol; 2011 Apr; 164(4):862-72. PubMed ID: 21332467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT).
    Paul C; Puig L; Kragballe K; Luger T; Lambert J; Chimenti S; Girolomoni G; Nicolas JF; Rizova E; Lavie F; Mistry S; Bergmans P; Barker J; Reich K;
    Br J Dermatol; 2014 Feb; 170(2):425-34. PubMed ID: 24116959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis.
    Reich K; Puig L; Paul C; Kragballe K; Luger T; Lambert J; Chimenti S; Girolomoni G; Nicolas JF; Rizova E; Brunori M; Mistry S; Bergmans P; Barker J;
    Br J Dermatol; 2014 Feb; 170(2):435-44. PubMed ID: 24116868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis.
    Langley RG; Papp K; Gottlieb AB; Krueger GG; Gordon KB; Williams D; Valdes J; Setze C; Strober B
    J Eur Acad Dermatol Venereol; 2013 Oct; 27(10):1252-61. PubMed ID: 23157612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection.
    Tsai TF; Ho V; Song M; Szapary P; Kato T; Wasfi Y; Li S; Shen YK; Leonardi C;
    Br J Dermatol; 2012 Nov; 167(5):1145-52. PubMed ID: 22803615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study.
    Leonardi C; Sobell JM; Crowley JJ; Mrowietz U; Bao Y; Mulani PM; Gu Y; Okun MM
    Br J Dermatol; 2012 Sep; 167(3):658-67. PubMed ID: 22564148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
    Papp K; Gottlieb AB; Naldi L; Pariser D; Ho V; Goyal K; Fakharzadeh S; Chevrier M; Calabro S; Langholff W; Krueger G
    J Drugs Dermatol; 2015 Jul; 14(7):706-14. PubMed ID: 26151787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignancy Rates in Brodalumab Clinical Studies for Psoriasis.
    Gottlieb A; Lebwohl M; Liu C; Israel RJ; Jacobson A
    Am J Clin Dermatol; 2020 Jun; 21(3):421-430. PubMed ID: 32207067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy.
    Goffe B; Papp K; Gratton D; Krueger GG; Darif M; Lee S; Bozic C; Sweetser MT; Ticho B
    Clin Ther; 2005 Dec; 27(12):1912-21. PubMed ID: 16507377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.
    van de Kerkhof PC; Griffiths CE; Reich K; Leonardi CL; Blauvelt A; Tsai TF; Gong Y; Huang J; Papavassilis C; Fox T
    J Am Acad Dermatol; 2016 Jul; 75(1):83-98.e4. PubMed ID: 27180926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up.
    Langley RG; Lebwohl M; Krueger GG; Szapary PO; Wasfi Y; Chan D; Hsu MC; You Y; Poulin Y; Korman N; Prinz JC; Reich K;
    Br J Dermatol; 2015; 172(5):1371-83. PubMed ID: 25307931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies.
    Reich K; Papp KA; Armstrong AW; Wasfi Y; Li S; Shen YK; Randazzo B; Song M; Kimball AB
    Br J Dermatol; 2019 May; 180(5):1039-1049. PubMed ID: 30485400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations.
    Menter A; Reich K; Gottlieb AB; Bala M; Li S; Hsu MC; Guzzo C; Diels J; Gelfand JM
    J Drugs Dermatol; 2008 Dec; 7(12):1137-46. PubMed ID: 19137767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data.
    Strober B; Leonardi C; Papp KA; Mrowietz U; Ohtsuki M; Bissonnette R; Ferris LK; Paul C; Lebwohl M; Braun DK; Mallbris L; Wilhelm S; Xu W; Ljungberg A; Acharya N; Reich K
    J Am Acad Dermatol; 2017 Mar; 76(3):432-440.e17. PubMed ID: 27889292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.